ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2910

How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test?

Jorge Medina-Rosas1, Murray Urowitz2,3, Jiandong Su2, Dafna Gladman2 and Zahi Touma2, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: proteinuria and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Protein/Creatinine ratio in a spot urine sample (PCR) has been accepted as a substitute for the protein content in a 24 hours urine collection (24H-P), but there is not enough evidence on its usefulness for the prospective follow up of lupus patients.  The purpose of this study was to determine if PCR can accurately measure the change in proteinuria level over time when compared to the “gold standard” test 24H-P.

Methods: Analysis on data from a single lupus centre between May 2008 and December 2014 was conducted. Results of concurrent urine samples for PCR and 24H-P were identified. Patients with diabetes mellitus, end stage kidney disease and kidney transplantation were excluded.

The gold standard test in this study is 24H-P. At baseline visit, urine samples with abnormal 24H-P (³0.5 g/day) and normal 24H-P (<0.5 g/day) were identified. In the group with abnormal 24H-P, the first follow up visit for each patient with 50 and 100% improvement, based on 24H-P, was identified and compared to the PCR results at this visit. In the group with normal 24H-P, the first follow up visit for each patient with worsening (³0.5 g/day) based on 24H-P was identified and compared to the PCR results at this visit. Abnormal PCR is >0.05 g/mmol.

Standardized Response Mean (SRM) for 24H-P and PCR for 50 and 100% improvement and for worsening were calculated. We hypothesized that both tests (24H-P and PCR) will change in the same direction but the effect captured by 24H-P is larger than PCR.

Results: 

1188 paired samples from 230 patients.

  • 24H-P 100% improvement: 60 patients started with abnormal 24H-P (³0.5 g/day) and had 100% improvement on follow up. Mean duration for improvement: 17.5 months. Among this group, only 53.3% had 100% improvement based on PCR. SRM for 24H-P: -1.00 (95% CI: -1.31 to -0.69) (large effect). SMR for PCR: -0.69 (95%CI: -0.97 to -0.41) (moderate effect).
  • 24H-P 50% improvement: 64 patients started with abnormal 24H-P (³0.5 g/day) and had 50% improvement on follow up. Mean duration for improvement: 13.6 months. Among this group, only 56% of patients had 50% improvement based on the PCR. SRM for 24H-P: -1.27 (95% CI: -1.61 to -0.95) (large effect). SMR for PCR is -0.63 (95% CI: -0.90 to -0.36) (moderate effect).
  • 24H-P worsening: 43 patients started with normal 24H-P (<0.5 g/day) and became abnormal (³0.5 g/day) on follow up. Mean duration for worsening of proteinuria: 10.5 months. At first visit all patients had normal 24H-P but 34.9% had abnormal PCR (≥0.5 mg/g). At the first visit with abnormal 24H-P, only 79.1% of these patients had abnormal results by PCR. SRM for 24H-P: 0.81 (95% CI: 0.46 to 1.15) (large effect). SMR for PCR: 0.53 (95%CI: 0.21 to 0.85) (moderate effect).

Magnitude of change for improvement (50 and 100%) and worsening: SRM24H-P > SRMPCR

Conclusion: PCR is not as accurate as 24H-P in determining clinically important change in proteinuria levels (50, 100% improvement and 100% worsening) in lupus nephritis. Thus 24 H-P should be used to monitor improvement or deterioration in LN in clinical practice.


Disclosure: J. Medina-Rosas, None; M. Urowitz, None; J. Su, None; D. Gladman, None; Z. Touma, None.

To cite this abstract in AMA style:

Medina-Rosas J, Urowitz M, Su J, Gladman D, Touma Z. How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/how-accurate-is-spot-urine-proteincreatinine-ratio-in-measuring-the-change-over-time-in-proteinuria-level-compared-to-the-24-hour-proteinuria-test/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-accurate-is-spot-urine-proteincreatinine-ratio-in-measuring-the-change-over-time-in-proteinuria-level-compared-to-the-24-hour-proteinuria-test/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology